Category Archives: Tofacitinib

2018 American Hair Research Summit

One of the less desirable aspects about writing this blog is learning new acronyms or alphanumeric product names virtually every week. Half way into this month, my street cred has already been enhanced by “SFRP1”, “WAY-316606” and “HSC660”. Today come “AHRS” and “IID”.

AHRS 2018

Recently, I learnt that the American Hair Research Summit (AHRS) is holding its first conference from May 14-16, 2018 in Orlando, Florida  at the Rosen Shingle Creek Resort. Having covered numerous US and global hair loss conferences on this blog in the past, I did not recall having ever heard of the “AHRS”. It seems like this is the first ever conference being held by this newly formed association.

On their website, they state the following:

“The American Hair Research Society (AHRS) is the former North American Hair Research Society (NAHRS). Because of the great interest and contributions in hair research from colleagues in Central and South America, the “NAHRS” has expanded to “AHRS”.

The AHRS has manged to get an excellent list of speakers and presenters at its first ever summit. Some points of interest:

  • Final Program Guide.
  • Abstract Book.
  • For a majority of us, the most interesting presentations are under the session titled as “Stem Cells, Hair Follicle Neogenesis & Regenerative Medicine”.
  • A number of you posted various links in relation to Aclaris Therapeutics’ press release about this conference. I removed all of them because I did not want that discussion to take place in the comments to my prior posts. The key sentence in this latest Aclaris press release is: “Current efforts to expand the range of diseases that could be targeted with JAK inhibitors will be discussed with emphasis on hair disorders, including alopecia areata and androgenetic alopecia.”
  • The Aclaris presenter Dr. Paul Changelian is an extremely respected researcher when it comes to JAK inhibitors. Especially Tofacitinib.
  • Aclaris and Samumed are both Silver level sponsors of this event.
  • Update: One of my inside sources e-mailed me today and said that there was some excitement about the results presented by Cassiopeia in relation to Breezula. Before anyone gets too excited, remember that Breezula is just a topical anti-androgen and unlikely to cause totally balding regions of the scalp to regain their past glory. Nevertheless, a good maintenance treatment in itself would be very welcome.
  • Dr. George Cotsarelis chairs an important session titled “PRP: Hope or Hype?”. A number of other presentations on PRP are also worth tracking.
  • Also a number of presentations on the similarly controversial laser and hair growth subject in the session titled “Photobiomodulation, Thermal and Light Therapies”.
  • The women continue to take over. The four co-chairs:
Angela Christiano
Dr. Christiano
Maria Hordinsky
Dr. Hordinsky
Wilma Bergfeld
Dr. Bergfeld
Antonella Tosti
Dr. Tosti

 

 

 

IID 2018

Interestingly, the International Investigative Dermatology (IID) 2018 Meeting is also being held at the exact same Rosen Shingle Creek Resort location in Orlando from May 16-19, 2018. I am not too impressed with some parts of the IID 2018 website, but Aclaris is making several interesting presentations at this event.

In the first of those links, one of the abstracts is titled:

Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia“, and the author is from Thailand. Usually, the JAK inhibitor related studies are authored by US based scientists, so this is a nice change.

Non-scarring alopecia includes androgenetic alopecia, so I looked around and found this paper by the same author. Interesting that so much varied research over the years has found VEGF to be so important for hair growth.

Also of note is the fact that so many of the Aclaris presentations entail tofacitinib. We are still not 100% sure as to which of the various “-tinib” JAK inhibitors and their combinations the company is modifying and using in its much anticipated covalently bound topical JAK inhibitor product for treating androgenetic alopecia.

However, it looks like a certainty that some variation of tofacitinib will be a major component of the final product.

Brief Items of Interest, January 2018

Kerastem STYLE phase II clinical trial results update. Somewhat positive news of 17 percent increase in hair count at 6 months post-treatment. However, they only treated men in the early stages of hair loss (Norwood Scale I to III).

Regenerating one pigmented hair follicle
Single hair follicle regeneration in elderly man after wounding.

— Reader “omg” posted an interesting link to a study from Taiwan with a great title: “Never too old to regenerate (hair)”. The researchers report on an 80 year old man who regrew 1 brand new pigmented black hair after scalp wounding due to excision of a basal cell carcinoma. Yet more evidence in support of wounding, the main idea behind the work of well known company Follica. The new (or regenerated old) hair remained black at the 42-month time of follow-up. I do not think the claim that the researchers make that this is the world’s first case of wounding led hair growth in human skin is true.

— A potential improvement in current hair regeneration technology from Japan via self-sorted hair follicle germs (ssHFGs). I visualize an image of ant collaboration (which creeps me out a bit), each time I read that term. Dr. Junji Fukuda who I have covered on this blog before is a lead author. Update: A new article on this development came out on February 1, 2018.

— Dr. Takashi Tsuji was back in the news a couple of weeks ago. He is leading a Japanese team that includes RIKEN researchers that will develop technology to analyze human health ramifications of changes in people’s hair shape and quality. According to Dr. Tsuji, some research indicates that certain changes in human hair components are unique to people with diseases such as cancer and diabetes. Perhaps in future one can detect cancer earlier depending on hair analysis.

— Discussion about Donald Trumps’s hair never seems to get old when it comes to the major newspapers. I previously discussed Mr. Trump’s usage of Finasteride as well as a 10 page detailed article on his hair. Now come news that his daughter Ivanka has claimed that Donald Trump has had scalp reduction surgery.

Hair transplants could cure migraines in some per Turkish surgeon Dr. Safvet Ors. Actual study was published a few months ago despite major newspapers only covering the development more recently.

Topical Tofacitinib 2% ointment at least moderately effective in 3 of 10 patients suffering from alopecia areata. Dr. Brett King led the study. Hopefully, Aclaris will see better results for male pattern hair loss sufferers with their topical JAK product when it finally comes out. Fingers crossed.